Cambridge Investment Research Advisors
FTXH icon

Cambridge Investment Research Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
30,525
+10,985
+56% +$383K ﹤0.01% 1997
2026
Q1 		$671K Buy
19,540
+3,924
+25% +$134K ﹤0.01% 2546
2025
Q4 		$514K Buy
15,616
+343
+2% +$10.7K ﹤0.01% 2696
2025
Q3 		$436K Sell
15,273
-1,713
-10% -$46.6K ﹤0.01% 2797
2025
Q2 		$435K Buy
16,986
+419
+3% +$10.6K ﹤0.01% 2669
2025
Q1 		$455K Buy
16,567
+2,663
+19% +$73.7K ﹤0.01% 2535
2024
Q4 		$375K Buy
+13,904
New +$390K ﹤0.01% 2658
2023
Q3 		– Sell
-15,572
Closed -$408K – 3185
2023
Q2 		$408K Sell
15,572
-8,151
-34% -$215K ﹤0.01% 2283
2023
Q1 		$619K Buy
23,723
+5,808
+32% +$156K ﹤0.01% 1942
2022
Q4 		$491K Buy
+17,915
New +$477K ﹤0.01% 2027

Other funds holding FTXH

NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Cambridge Investment Research Advisors's FTXH Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 56% in Q2 2026, buying an estimated $383K and bringing the position to 30,525 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Cambridge Investment Research Advisors first reported a position in FTXH in Q4 2022 and has held it in 10 quarters since. 8 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • Cambridge Investment Research Advisors held 30,525 shares of First Trust Nasdaq Pharmaceuticals ETF worth $1.17M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 10,985 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $383K.
  • First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1997 holding.
  • Cambridge Investment Research Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and has held it in 10 quarters since.
  • 8 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.